Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17048433 | 0.92 | ALDH1A1 (0.85) | ALDH1A1SMN1; SMN2EPHX2HTR2CTDP1 | |
| SCHEMBL29668383 | 0.91 | ALDH1A1 (0.82) | ALDH1A1SMN1; SMN2EPHX2HTR2CTDP1 | |
| SCHEMBL15453396 | 0.90 | ALDH1A1 (0.81) | ALDH1A1SMN1; SMN2TDP1TSHRGAA | |
| SCHEMBL5523975 | 0.86 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2TDP1TSHRGAA | |
| SCHEMBL13746152 | 0.85 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2EPHX2TSHRPOLB | |
| SCHEMBL17182848 | 0.84 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2TDP1TSHRGAA | |
| SCHEMBL17182903 | 0.84 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2TDP1TSHRGAA | |
| SCHEMBL17182851 | 0.84 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2TDP1TSHRGAA | |
| SCHEMBL2447403 | 0.84 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HTR2CTDP1TSHR | |
| SCHEMBL13745651 | 0.84 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2HTR2CTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| CN-116438167-A | Compounds having O-GlcNAc enzyme inhibitory activity and uses thereof | 美迪福伦DBT有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2009098282-A1 | LOW MOLECULAR WEIGHT 2,5-DISUBSTITUTED THIOPHENE DERIVATIVES AND USE THEREOF IN THERAPY | NOVASAID AB (SE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | OGA, OGT, ENGASE | ALDH1A1 1141/4885SMN1; SMN2 4435/4885EPHX2 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.